Dorit Koren, n/a

Rhythm Pharmaceuticals, Inc.
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• SAT-713 - Setmelanotide, a Melanocortin-4 Receptor Agonist, in Prader-Willi Syndrome: Initial Phase 2 Results

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT